l Myydyimmät syöpälääkkeet

40 myydyintä syöpälääkettä 2023 (2022)  

https://xtalks.com/top-40-best-selling-cancer-drugs-in-2023-by-2022-data-3702/  

 

Pystysasteikko: myynti miljardeja $. Suurin myynti Keytruda n. 21 mrd$

Kirjoituksessa kuvataan kohde, luvat, hoidot, kustannukset...

1. Keytruda (Pembrolizumab), valmistaja Merck, myyntilupa 9/2014,

Hoidot: "Indications Keytruda is FDA-approved for: Breast cancer, melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer, urothelial carcinoma, microsatellite instability-high or a mismatch repair deficient solid tumor, colon or rectal cancer, esophageal or certain gastroesophageal junction carcinomas, cervical cancer, renal cell carcinoma, endometrial carcinoma and cutaneous squamous cell carcinoma." - siis on normaalia, että lääke tehoaa useisiin syöpätyyppeihin.

Hoidon hinta: 11'000 $ per annos, hoito 3 viikkoa...

"Price of Keytruda: $11,115.04 for each indicated dose when given for three weeks and $22,230.08 when administered every six weeks."

Miksi lääke oli niin tehokas? PD-1, ohjelmoitu solukuolema, tehokas haastavissa syöpätyypeissä, tehokas sekä erillisenä että yhdistelmähoidoissa

"Why it did so well: Keytruda was first approved in 2014 for advanced melanoma and a decade later, it has approvals in 39 indications across over 20 different cancer types in the US, with its most recent in late-stage cervical cancer granted by the FDA in January 2024. The programmed death receptor-1 (PD-1) immune checkpoint inhibitor is not only Merck’s reigning blockbuster but also remains one of the best-selling drugs globally, and is expected to be the world’s top seller in 2024. Keytruda has proven to be such a mammoth success given its effectiveness across a range of different cancers, particularly in challenging, advanced cancers. It has demonstrated significant effectiveness as a monotherapy as well as in combination therapies, lending to its versatility. Moreover, its enduring effectiveness was highlighted by recent findings presented at the European Society for Medical Oncology (ESMO) annual meeting last September. In the studies, a combination of Keytruda and chemotherapy led to nearly 20 percent of patients with NSCLC surviving for five years."

OOO

synergiaa...?